Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

586
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
586
Long-term Depression01:03

Long-term Depression

2.8K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.8K
Long-term Depression01:05

Long-term Depression

32.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
32.4K
Long-term Potentiation01:35

Long-term Potentiation

57.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
57.2K
Long-term Potentiation01:25

Long-term Potentiation

3.1K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.

Nature communications·2026
Same author

Nucleoside-Analog Reverse-Transcriptase Inhibitors (NRTIs) Against Multiple Sclerosis: Comprehensive Review on a Possible Novel Therapeutic Approach.

Neurology international·2026
Same author

CnQuant: high-resolution chromosomal copy number profiling for precision oncology in the clinics.

Acta neuropathologica·2026
Same author

Neurolymphatic clearance in neurodegenerative disease: Emerging mechanisms and potential translational strategies.

JPRAS open·2026
Same author

Advancing CNS tumor diagnostics with expanded DNA methylation-based classification.

Cancer cell·2025
Same author

IDH mutations are rare events in SHH medulloblastoma.

Acta neuropathologica·2025

Related Experiment Video

Updated: Nov 20, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.6K

Severe oligomeric tau toxicity can be reversed without long-term sequelae.

Alfonso Martinisi1,2, Martin Flach1,2, Frederik Sprenger1,2

  • 1Institute of Medical Genetics and Pathology, University Hospital Basel, CH-4031 Basel, Switzerland.

Brain : a Journal of Neurology
|January 23, 2021
PubMed
Summary

Toxic tau species can cause reversible paralysis and neuronal dysfunction in mice. Recovered mice showed no long-term motor deficits or increased tau pathology, indicating effective clearance without seeding effects.

Keywords:
Alzheimer’s diseaseneurodegenerationoligomersseedingtau

More Related Videos

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.5K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.7K

Related Experiment Videos

Last Updated: Nov 20, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.6K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.5K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.7K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Neurodegenerative Diseases

Background:

  • Tau protein stabilizes microtubules but forms toxic aggregates in neurodegenerative disorders like Alzheimer's disease.
  • Previous studies demonstrated reversible paralysis in mice upon co-expression of fragmented and full-length tau.

Purpose of the Study:

  • To investigate the long-term motor function and tau pathology in mice recovered from tau-induced paralysis.
  • To assess the seeding competence of toxic oligomeric tau species.

Main Methods:

  • Studied long-term motor fitness in recovered P301SxTAU62on-off mice.
  • Inoculated ALZ17 mice with brainstem homogenates from paralyzed P301SxTAU62on mice to evaluate seeding potential.

Main Results:

  • Recovered mice did not exhibit increased motor impairment or tau pathology compared to controls.
  • Toxic tau species were cleared effectively without inducing seeding effects.
  • Inoculated ALZ17 mice showed no long-term tau seeding effects from these toxic species.

Conclusions:

  • Neurotoxic tau species can exist independently of seeding-competent aggregates.
  • Complete clearance of toxic tau forms is possible without subsequent seeding or spreading.
  • Targeting non-fibrillar tau species may offer therapeutic benefits for tauopathies.
  • The lack of seeding competence in early toxic tau species suggests caution in using seeding-based diagnostic tests.